Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Other Non-Current Liabilities (2016 - 2025)

Macrogenics (MGNX) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 46.54% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 46.54% year-over-year, with the annual reading at $1.1 million for FY2025, 46.54% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.1 million at Macrogenics, down from $1.3 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $2.0 million in Q4 2024, with the low at $258000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $592700.0, with a median of $258000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities tumbled 88.51% in 2021, then soared 662.79% in 2024.
  • Over 5 years, Other Non-Current Liabilities stood at $258000.0 in 2021, then changed by 0.0% to $258000.0 in 2022, then changed by 0.0% to $258000.0 in 2023, then skyrocketed by 662.79% to $2.0 million in 2024, then plummeted by 46.54% to $1.1 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.1 million, $1.3 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.